Glaukos Corporation GKOS

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
50/100
Moderate

About Glaukos Corporation

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite … Full GKOS analysis →

Competitive advantage assessment

Key strengths

  • Improving FCF Trend FCF trend score is positive (score 0.61). Improving FCF margin signals compounding operational leverage.
  • Durable Revenue Growth Revenue growth trend is strong (score 0.95). Durable top-line expansion confirms the razor-and-blade flywheel is working.

Key risks

  • Thin Interest Coverage Interest coverage lags peers (score 0.21). Thin coverage limits M&A optionality and raises refinancing risk.
  • Gross Margin Volatility Gross margin stability is poor (score 0.24). Margin volatility undermines the consumable moat thesis.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Developing
37

Where GKOS ranks in Medical Devices

Glaukos Corporation ranks #72 of 160 scored companies in Medical Devices by moat score — the top 45%. The widest moat in the group is iRadimed Corporation (IRMD) at 83/100.

Moat scores for companies ranked near GKOS in Medical Devices
# Company Moat score Rating
68 Aethlon Medical, Inc. AEMD 51/100 Moderate
69 Apyx Medical Corporation APYX 51/100 Moderate
70 Cytek Biosciences, Inc. CTKB 50/100 Moderate
71 Avita Medical, Inc. RCEL 50/100 Moderate
72 Glaukos Corporation GKOS 50/100 Moderate
73 908 Devices Inc. MASS 49/100 Developing
74 Quantum-Si Incorporated QSI 49/100 Developing
75 Quantum-Si incorporated QSIAW 49/100 Developing
76 Owlet, Inc. OWLT 49/100 Developing

See every Medical Devices & Diagnostics company ranked by moat score →

How GKOS scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Score 37 · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Score 55 · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Score 61 · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Score 47 · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Score 36 · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Score 76 · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding GKOS's moat

What is Glaukos Corporation's moat score?

Glaukos Corporation (GKOS) scores 50 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #72 of 160 scored companies in Medical Devices, the top 45%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 159 companies in Medical Devices. Its strongest defense is Growth Durability (76/100) and its weakest is Capital Structure & Resilience (36/100).

How does Glaukos Corporation compare with other Medical Devices companies?

Glaukos Corporation ranks #72 of 160 scored companies in Medical Devices by moat score. The widest moat in Medical Devices is iRadimed Corporation (IRMD) at 83/100. The companies ranked closest are Avita Medical, Inc. (RCEL) at 50 just above it and 908 Devices Inc. (MASS) at 49 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 159 companies in Medical Devices. The defenses are then weighted to produce the overall score out of 100.

Why is Glaukos Corporation scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Glaukos Corporation?

The Medical Devices & Diagnostics template measures 6 defenses, and GKOS scores: Pricing Power & Consumable Moat (37), R&D Pipeline & Capital Returns (55), FCF Quality & Cash Conversion (61), Commercial Execution (47), Capital Structure & Resilience (36), Growth Durability (76). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000